Related Experiment Video
Updated: Aug 19, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at
Ulrike Bacher1, Torsten Haferlach, Wolfgang Hiddemann
1Laboratory for Leukemia Diagnostics, Department for Internal Medicine III, Klinikum Grosshadern, Ludwig-Maximilians-University, Marchioninistrasse 15, D-81377 Munich, Germany. ulrike.bacher@med.uni-muenchen.de
Insights
Cytogenetic patterns in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML) differ significantly at diagnosis and during disease progression. Karyotype analysis helps distinguish CML blast crisis from Ph+ ALL.
Area of Science:
- Hematology
- Oncology
- Cytogenetics
Background:
- Philadelphia translocation (Ph+) is a hallmark of certain leukemias, including Ph+ acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML).
- Cytogenetic heterogeneity is observed in these Ph+ leukemias, necessitating detailed investigation.
Purpose of the Study:
- To compare the cytogenetic patterns of Ph+ ALL and CML at diagnosis and during disease progression.
- To determine if karyotype analysis can differentiate lymphoid blast crisis of CML from de novo Ph+ ALL.
Main Methods:
- Karyotype analysis was performed on 154 patients with Ph+ ALL (at diagnosis or relapse) and 174 patients with CML (in various phases).
- Comparative analysis of chromosomal aberrations and karyotype complexity was conducted.
Main Results:
- Ph+ ALL at diagnosis showed heterogeneous cytogenetic patterns with frequent numerical and structural aberrations.
- CML at diagnosis typically presented with rare additional chromosomal changes.
- Ph+ ALL progression to relapse involved increased aberrations, but the pattern remained similar.
- CML progression to advanced phases was marked by new chromosomal changes and increased karyotype complexity.
- Lymphoid blast crisis of CML exhibited distinct karyotypes compared to de novo Ph+ ALL.
Conclusions:
- Cytogenetic patterns of Ph+ ALL and CML are distinct at diagnosis.
- Ph+ ALL and CML follow different evolutionary pathways during disease progression or relapse.
- Karyotype analysis is a valuable tool for discriminating between de novo lymphoid blast crisis of CML and de novo Ph+ ALL.
Abstract:
The cytogenetic patterns in addition to the Philadelphia translocation in Philadelphia-positive (Ph+) ALL and chronic myeloid leukemia (CML) is heterogenous. We investigated 154 patients with Ph+ ALL at diagnosis or at relapse and 174 patients with different phases of CML. Ph+ ALL at diagnosis demonstrated a heterogenous pattern with a high frequency of numerical and structural chromosomal aberrations. CML at diagnosis presented with rare additional chromosomal changes. In Ph+ ALL, the pathway from diagnosis to relapse was characterized by the acquisition of a higher number of chromosomal aberrations, but the pattern of frequent aberrations at relapse did not differ from that observed at diagnosis. In contrast, in CML the pathway from chronic to the advanced phases was characterized by the acquisition of new chromosomal changes and by the development of karyotype complexity. In addition, the investigation of 10 cases of lymphoid blast crisis of CML showed significant differences in the karyotype in comparison to Ph+ ALL at diagnosis. Therefore, the karyotype can be helpful in discriminate de novo lymphoid blast crisis of CML from de novo Ph+ ALL. In conclusion, we were able to demonstrate that the cytogenetic patterns of Ph+ ALL and of CML are different at diagnosis and furthermore follow different pathways during progression or relapse.
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Differentiation of Common Myeloid Progenitor Cells
